Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: HIV Infections
Interventions: Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson's Disease (PD)
Interventions: TB006, Placebo; Drug
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Aliso Viejo, California • Palo Alto, California • Englewood, Colorado + 11 more

Conditions: Healthy Participants, Mild Cognitive Impairment
Interventions: LLLT, Placebo; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 45 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatitis C
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 18
States / cities: San Diego, California • Ventura, California • Bradenton, Florida + 13 more

Conditions: Atrial Fibrillation
Interventions: (R)-propafenone, (S)-Propafenone, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: IBS
Interventions: VSL#3; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Muscle Strength, Botulinum Toxins, Type A
Interventions: Botulinum Toxin, Type A, Saline; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 54 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Loma Linda, California

Conditions: Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions: Remodulin® (treprostinil sodium) Injection; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Colorectal Cancer
Interventions: aspirin, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 30 Years to 74 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2006
U.S. locations: 41
States / cities: Scottsdale, Arizona • San Francisco, California • Miami Beach, Florida + 37 more

Conditions: Depression
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 25 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Culturelle (Lactobacillus rhamnosus strain GG), Placebo; Dietary Supplement · Other
Lead sponsor: Northwell Health; Other
Eligibility: 5 Years to 18 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: COVID-19 Pulmonary Complications, COVID-19
Interventions: Zanubrutinib, Supportive Care, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Fullerton, California • Washington D.C., District of Columbia • Thomasville, Georgia + 6 more

Conditions: Obesity
Interventions: Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pruritus, Pregnancy Related
Interventions: Promethazine, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Migraine With or Without Aura
Interventions: Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation
Interventions: Zolpidem CR, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: BACTERIAL VAGINOSIS
Interventions: RIFAXIMIN VAGINAL TABLET 25 MG, RIFAXIMIN VAGINAL TABLET 100 MG, PLACEBO VAGINAL TABLET, METROGEL VAGINAL; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Biliary Cirrhosis
Interventions: Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more

Conditions: Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
Interventions: Lithium Carbonate, Placebo, Citalopram; Drug
Lead sponsor: Columbia Northwest Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: San Diego, California • Bellevue, Washington

Conditions: Cocaine Dependence
Interventions: Modafinil, Sugar Pill, Contingency Management, Methadone, cognitive behavioral treatment, Voucher Control; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Osteopenia
Interventions: Melatonin 5 mg, Osteogenic loading, Mock for Osteogenic Loading, Placebo (plant fiber) for melatonin; Drug · Device
Lead sponsor: Duquesne University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Endometriosis
Interventions: DR-2001a, DR-2001b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 41
States / cities: Enterprise, Alabama • Montgomery, Alabama • Phoenix, Arizona + 38 more

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Crohn's Disease
Interventions: GED-0301, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 12 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: San Diego, California • Atlanta, Georgia • Indianapolis, Indiana + 18 more

Search by objective public record fields.

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

Cognitive Enhancement Through Transcranial Laser Therapy

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

New Formulations of Propafenone to Treat Atrial Fibrillation

Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit

Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

Effect of DPP4 Inhibition on Growth Hormone Secretion

Treatment of Pruritus With Intramuscular Promethazine

An Acute Migraine Factorial Study

Zolpidem CR and Hospitalized Patients With Dementia

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

Pharmacotherapy & CM for Opioid and Cocaine Dependence

Melatonin and Osteogenic Loading on Osteopenia

Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease